This segment focuses on the research and development of IgM antibody therapeutics for the treatment of various cancers, including B cell Non-Hodgkin's lymphoma (NHL) and solid tumors. Research and development activities include the design, engineering, and preclinical testing of IgM antibodies, followed by clinical trials to evaluate safety and efficacy. The primary technology platform is based on engineered IgM antibodies, such as IGM-2323 and IGM-8444. These bispecific antibodies are designed to target cancer cells while also engaging the immune system. Patient impact is addressed by providing novel treatment options for patients with relapsed/refractory cancers, potentially improving survival rates and quality of life. Market positioning is based on the development of a new class of antibody therapeutics with the potential to overcome limitations of existing treatments. Future opportunities include expanding the pipeline to include additional cancer indications and developing combination therapies. Regulatory and clinical aspects involve conducting Phase 1 clinical trials and working towards FDA approval. Partnerships and collaborations include agreements with companies like ADC Therapeutics for clinical trials.

This segment is dedicated to the development of IgM antibody therapeutics for autoimmune and inflammatory diseases. Research and development efforts involve identifying and validating targets, designing and engineering IgM antibodies, and conducting preclinical and clinical studies. The core technology platform centers around engineered IgM antibodies, which are designed to modulate the immune system and reduce inflammation. The therapeutic focus is on addressing diseases with high unmet medical needs, potentially improving patient outcomes and quality of life. Market positioning is based on the development of a novel class of medicines with the potential to offer improved efficacy and safety compared to existing treatments. Future opportunities include expanding the pipeline to include additional autoimmune diseases and developing combination therapies. Regulatory and clinical aspects involve conducting clinical trials and working towards regulatory approvals. Partnerships and collaborations are key to advancing the development and commercialization of these therapies.